Burkitt Lymphoma
An extremely fast-growing blood cancer of B-cells, often presenting as a large jaw or abdominal mass, requiring immediate intensive chemotherapy.
Emergency Management: Tumor Lysis Syndrome. Requires emergent IV hydration (2-3 times maintenance), Rasburicase 0.2 mg/kg IV once, and close monitoring of electrolytes. Dialysis is required if acute kidney injury progresses despite medical management.
A highly aggressive B-cell non-Hodgkin lymphoma characterized by the translocation and deregulation of the MYC gene on chromosome 8. It is one of the fastest-growing human tumors, with a Ki-67 proliferation index of nearly 100%.
Detailed Overview
There are three clinical variants: Endemic (African, strongly linked to Epstein-Barr Virus and presenting as jaw/facial bone lesions in children), Sporadic (worldwide, presenting as an abdominal mass), and Immunodeficiency-associated (primarily in HIV/AIDS patients). The disease is a medical emergency due to its rapid growth and high risk of spontaneous or treatment-induced tumor lysis syndrome.
Epidemiology & Demographics
Endemic variant is the most common childhood cancer in equatorial Africa. Sporadic variant accounts for 1-2% of adult lymphomas but up to 30% of childhood lymphomas in the US/Europe. Peak age for sporadic is 3-12 years; male to female ratio is 3-4:1.
Etiological Mechanism
Driven by chromosomal translocations involving the MYC oncogene on chromosome 8 and immunoglobulin heavy or light chain loci. The most common is t(8;14)(q24;q32). EBV infection is a major co-factor, found in >95% of endemic cases and 20-30% of sporadic cases.
Primary Causes
["MYC gene translocation", "Epstein-Barr Virus (EBV) co-infection", "HIV-induced immunosuppression"]
The t(8;14) translocation places the MYC proto-oncogene under the control of the highly active Ig heavy chain promoter. This leads to constitutive overexpression of the c-Myc protein, a transcription factor that drives continuous cellular proliferation and inhibits apoptosis. The tumor doubles in size every 24-48 hours.
Diagnostic Criteria & Guidelines
Tissue biopsy (excisional node or mass biopsy). Histology shows sheets of medium-sized, highly proliferative B-cells with interspersed tingible body macrophages containing apoptotic debris (classic 'starry sky' appearance). IHC is positive for CD19, CD20, CD10, BCL6; negative for BCL2; Ki-67 fraction > 95%. Cytogenetics confirm MYC translocation.
Intensive, short-duration combination chemoimmunotherapy. The CODOX-M/IVAC regimen (Cyclophosphamide, Vincristine, Doxorubicin, High-dose Methotrexate / Ifosfamide, Etoposide, High-dose Cytarabine) combined with Rituximab (375 mg/m2). Mandatory CNS prophylaxis with intrathecal methotrexate and cytarabine.
Second-Line & Adjunctive Therapy
For relapsed/refractory disease: R-ICE (Rituximab, Ifosfamide, Carboplatin, Etoposide) followed by autologous hematopoietic stem cell transplant, or CAR-T cell therapy (e.g., Axicabtagene ciloleucel).
Surgical & Procedural Management
Generally not indicated, except for diagnostic biopsy or emergency management of bowel obstruction/perforation.
Patient Counseling & Advice
Inform patients/parents that the tumor grows alarmingly fast, but precisely because it divides so rapidly, it is highly sensitive to chemotherapy and frequently curable. Discuss the high risk of infertility with CODOX-M/IVAC.
Follow-Up & Monitoring Schedule
PET/CT upon completion of therapy to confirm complete metabolic response. Serial clinical exams and LDH checks every 3 months for the first year. Relapses almost always occur within the first year.
Preventive Strategies
No specific prevention. HIV management with HAART reduces the risk of the immunodeficiency variant.
Excellent with modern intense chemotherapy. Overall survival exceeds 80-90% in children and 70-80% in adults if treated promptly. Prognosis is poor if CNS is heavily involved at diagnosis.